Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
July 31, 2023 16:30 ET
|
Cidara Therapeutics, Inc.
Cidara’s U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 (GLOBE...
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
July 20, 2023 17:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Added to Russell Microcap® Index
June 26, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
June 22, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
June 20, 2023 09:55 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
June 13, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 16:37 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference
May 03, 2023 16:30 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™
April 24, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
– U.S. launch of REZZAYO by Melinta expected in mid-2023 –– Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on successful completion...
Cidara Therapeutics to Participate in Upcoming Investor Conferences
March 31, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...